Acid reflux has not been proven to cause pulmonary fibrosis, but a strong and concerning link exists between the two conditions. Up to 87% of people with idiopathic pulmonary fibrosis (IPF) have abnormal acid reflux, a rate far higher than in the general population. The leading theory is that tiny amounts of stomach contents repeatedly reach the lungs over months or years, a process called chronic microaspiration, potentially triggering or accelerating the scarring that defines pulmonary fibrosis.
How Stomach Contents Can Damage Lung Tissue
When reflux travels far enough up the esophagus, small amounts can slip past the upper airway and enter the lungs. This doesn’t require a dramatic choking event. Microaspiration often happens silently, especially during sleep, without coughing or any obvious warning. Once stomach acid, digestive enzymes like pepsin, and bile acids reach the delicate air sacs in the lungs, they set off a chain of damage.
Animal studies show that even a single dose of acid delivered to the lungs causes bleeding in the air sacs, fluid buildup, and an influx of immune cells. More importantly for fibrosis, acid exposure ramps up production of a signaling molecule called TGF-beta, which tells the body to lay down scar tissue. Bile acids in the reflux fluid do the same thing: a specific bile acid component triggers lung cells to produce TGF-beta and stimulates the growth of fibroblasts, the cells responsible for building scar tissue. Over time, this cycle of injury, inflammation, and abnormal wound healing can replace healthy, flexible lung tissue with stiff, fibrous scarring.
Evidence That Aspiration Is Happening
Researchers can detect pepsin, a stomach enzyme that has no business being in the lungs, in fluid washed from the airways of IPF patients. Most patients with stable IPF have measurable pepsin in their lungs, suggesting that silent aspiration is common in this population. In patients experiencing sudden flare-ups of their disease (called acute exacerbations), pepsin levels tend to be even higher. About a third of patients during these flare-ups had pepsin levels above 70 nanograms per milliliter, well beyond what’s found in stable patients. One patient’s pepsin level jumped roughly tenfold between a stable period and an acute exacerbation.
Higher pepsin levels also correlated with greater scarring visible on CT scans, reinforcing the idea that ongoing aspiration contributes to worsening lung damage.
The Chicken-or-Egg Problem
The central difficulty is figuring out which came first. Pulmonary fibrosis itself may promote reflux. As the lungs stiffen, the pressure changes across the diaphragm shift, and medications used to treat lung disease can relax the valve between the stomach and esophagus. So reflux could be a cause of fibrosis, a consequence of it, or both simultaneously, creating a vicious cycle.
Some researchers have proposed reflux as one of several possible triggers that initiates the disease in genetically susceptible people. In the MESA Lung Study, people with a hiatal hernia (where part of the stomach pushes up through the diaphragm, making reflux more likely) had 78% higher odds of developing early lung scarring visible on CT scans, particularly those under 80. The association was strongest in people who carried a specific genetic variant called MUC5B that’s already known to increase pulmonary fibrosis risk. Among carriers of this gene variant, having a hiatal hernia was linked to a noticeably faster yearly increase in lung scarring compared to non-carriers. This suggests reflux may be especially dangerous for people who are already genetically predisposed.
Still, no study has definitively proven that reflux alone can cause pulmonary fibrosis in an otherwise healthy person. The current scientific consensus treats reflux as a likely contributing factor, particularly in people with other risk factors, rather than a standalone cause.
Why You Might Not Feel the Reflux
Many IPF patients with severe, documented reflux never experience heartburn. This is because reflux that reaches the throat and airways, sometimes called laryngopharyngeal reflux or “silent reflux,” doesn’t always irritate the esophagus enough to cause the classic burning sensation. Instead, clues may include chronic throat clearing, hoarseness, a persistent cough, or a sensation of something stuck in the throat. In pulmonary fibrosis patients who already have a chronic cough from their lung disease, these signs can easily be overlooked.
This matters because 76% of IPF patients in one study had abnormal acid exposure in the lower esophagus, and 63% had it in the upper esophagus, the region closest to the airway. The fact that reflux reaches the upper esophagus in the majority of these patients means the potential for microaspiration is high, even in those who report no digestive symptoms at all.
How Reflux Testing Works in Pulmonary Fibrosis
Standard heartburn questionnaires miss too many cases in this population, so specialized testing is often used. The most informative test is impedance-pH monitoring, where a thin catheter is passed through the nose into the esophagus and worn for 24 hours. This catheter has sensors at multiple points along its length that detect both acidic and non-acidic reflux events, including those that travel all the way up to the upper esophagus near the airway.
Newer measurements from these tests are proving especially useful. One metric tracks how well the esophagus clears itself after a reflux event by measuring whether a normal swallowing reflex kicks in within 30 seconds. Another measures the baseline electrical resistance of the esophageal lining overnight, which drops when the tissue is chronically irritated. In IPF patients, abnormal results on these newer metrics have been linked to faster lung function decline, making them potentially valuable for identifying who might benefit most from reflux treatment.
Whether Treating Reflux Helps the Lungs
This is where the evidence gets complicated. Some observational studies have found that IPF patients taking acid-suppressing medications had slower lung function decline and fewer acute flare-ups. One analysis found that using these medications for more than four months was associated with lower IPF-related mortality compared to shorter use. Another post-hoc analysis showed that fewer patients on acid-suppressing therapy lost significant lung function (15% vs. 22%).
But these findings haven’t held up consistently. When data from multiple trials were combined, acid-suppressing treatment did not significantly affect disease progression, walking capacity, or survival. Some analyses even suggested that combining acid-suppressing drugs with the anti-fibrotic medication pirfenidone might worsen lung function. The positive results from observational studies may be skewed by lead time bias, where patients diagnosed earlier (and thus started on treatment earlier) appear to do better simply because their disease was caught sooner.
Anti-reflux surgery has also been studied. A randomized trial of 58 IPF patients found that those who had the procedure lost less lung capacity over 48 weeks than those who didn’t (a decline of 0.05 liters vs. 0.13 liters), but the difference was not statistically significant. Hospitalizations and deaths were also less common in the surgical group, again without reaching statistical significance.
What Current Guidelines Recommend
The most recent international clinical practice guideline, published jointly by the American Thoracic Society and three other major respiratory societies, recommends against using acid-suppressing medications or anti-reflux surgery specifically to improve lung outcomes in IPF. The evidence quality was rated as very low, and surgical complications occurred in up to 15% of patients in some studies.
However, the same guideline notes that treating reflux for its own sake remains appropriate. If you have both IPF and reflux symptoms, managing the reflux according to standard gastroenterology guidelines is still recommended. The distinction is an important one: current evidence doesn’t support treating reflux as a strategy to slow pulmonary fibrosis, but it also doesn’t rule out the possibility that controlling reflux matters, particularly in the subset of patients where microaspiration is clearly occurring.